Difference between revisions of "Crizotinib"

From Libre Pathology
Jump to navigation Jump to search
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
 
'''Crizotinib''' a drug used to treat lung cancer.  Its' trade name is ''Xalkori'' (Pfizer).<ref>URL: [https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/crizotinib https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/crizotinib]. Accessed on: November 8, 2018.</ref>  It is an [[ALK inhibitor]].
 
'''Crizotinib''' a drug used to treat lung cancer.  Its' trade name is ''Xalkori'' (Pfizer).<ref>URL: [https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/crizotinib https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/crizotinib]. Accessed on: November 8, 2018.</ref>  It is an [[ALK inhibitor]].
  
*Lung cancer with ROS1 rearrangement.<ref name=pmid25264305>{{Cite journal  | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref>
+
*[[Lung cancer with ROS1 rearrangement]].<ref name=pmid25264305>{{Cite journal  | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref>
 
*[[Lung carcinoma with ALK rearrangement]].<ref>{{Cite journal  | last1 = Wu | first1 = YL. | last2 = Lu | first2 = S. | last3 = Lu | first3 = Y. | last4 = Zhou | first4 = J. | last5 = Shi | first5 = YK. | last6 = Sriuranpong | first6 = V. | last7 = Ho | first7 = JCM. | last8 = Ong | first8 = CK. | last9 = Tsai | first9 = CM. | title = Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. | journal = J Thorac Oncol | volume =  | issue =  | pages =  | month = Jun | year = 2018 | doi = 10.1016/j.jtho.2018.06.012 | PMID = 29966800 }}</ref>
 
*[[Lung carcinoma with ALK rearrangement]].<ref>{{Cite journal  | last1 = Wu | first1 = YL. | last2 = Lu | first2 = S. | last3 = Lu | first3 = Y. | last4 = Zhou | first4 = J. | last5 = Shi | first5 = YK. | last6 = Sriuranpong | first6 = V. | last7 = Ho | first7 = JCM. | last8 = Ong | first8 = CK. | last9 = Tsai | first9 = CM. | title = Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. | journal = J Thorac Oncol | volume =  | issue =  | pages =  | month = Jun | year = 2018 | doi = 10.1016/j.jtho.2018.06.012 | PMID = 29966800 }}</ref>
 
*Lung carcinoma with MET amplification.<ref>{{Cite journal  | last1 = Forde | first1 = PM. | last2 = Rudin | first2 = CM. | title = Crizotinib  in the treatment of non-small-cell lung cancer. | journal = Expert Opin Pharmacother | volume = 13 | issue = 8 | pages = 1195-201 | month = Jun | year = 2012 | doi = 10.1517/14656566.2012.688029 | PMID = 22594847 }}</ref>
 
*Lung carcinoma with MET amplification.<ref>{{Cite journal  | last1 = Forde | first1 = PM. | last2 = Rudin | first2 = CM. | title = Crizotinib  in the treatment of non-small-cell lung cancer. | journal = Expert Opin Pharmacother | volume = 13 | issue = 8 | pages = 1195-201 | month = Jun | year = 2012 | doi = 10.1517/14656566.2012.688029 | PMID = 22594847 }}</ref>
  
Crizotinib has been largely subplanted by a new generation of ALK inhibitors that were designed to cross the blood-brain barrier.<ref name=pmid31331844>{{Cite journal  | last1 = Wrona | first1 = A. | title = Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed? | journal = Cancer Radiother | volume = 23 | issue = 5 | pages = 432-438 | month = Sep | year = 2019 | doi = 10.1016/j.canrad.2019.03.009 | PMID = 31331844 }}</ref>
+
Crizotinib has been largely subplanted by newer ALK inhibitors (ceritinib, brigatinib, lorlatinib) that were designed to cross the blood-brain barrier.<ref name=pmid31331844>{{Cite journal  | last1 = Wrona | first1 = A. | title = Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed? | journal = Cancer Radiother | volume = 23 | issue = 5 | pages = 432-438 | month = Sep | year = 2019 | doi = 10.1016/j.canrad.2019.03.009 | PMID = 31331844 }}</ref>
  
 
==See also==
 
==See also==

Latest revision as of 21:18, 30 December 2019

Crizotinib a drug used to treat lung cancer. Its' trade name is Xalkori (Pfizer).[1] It is an ALK inhibitor.

Crizotinib has been largely subplanted by newer ALK inhibitors (ceritinib, brigatinib, lorlatinib) that were designed to cross the blood-brain barrier.[5]

See also

References

  1. URL: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/crizotinib. Accessed on: November 8, 2018.
  2. Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  3. Wu, YL.; Lu, S.; Lu, Y.; Zhou, J.; Shi, YK.; Sriuranpong, V.; Ho, JCM.; Ong, CK. et al. (Jun 2018). "Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.". J Thorac Oncol. doi:10.1016/j.jtho.2018.06.012. PMID 29966800.
  4. Forde, PM.; Rudin, CM. (Jun 2012). "Crizotinib in the treatment of non-small-cell lung cancer.". Expert Opin Pharmacother 13 (8): 1195-201. doi:10.1517/14656566.2012.688029. PMID 22594847.
  5. Wrona, A. (Sep 2019). "Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?". Cancer Radiother 23 (5): 432-438. doi:10.1016/j.canrad.2019.03.009. PMID 31331844.